REG - Novacyt S.A. - AGM voting

Novacyt SAAnnouncement

11/10/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231011:nRSK7022Pa&default-theme=true

RNS Number : 7022P  Novacyt S.A.  11 October 2023

 

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

 

AGM voting

 

Paris, France, and Eastleigh UK - 11 October 2023 - Novacyt S.A. (EURONEXT
GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical
diagnostics, announces that shareholders are now able to vote for the
Company's rescheduled Annual General Meeting ("AGM"), which will be held at
1pm BST/2pm CEST on 26 October 2023 as an open meeting in Paris. All previous
votes remain valid for all meetings subsequently convened with the same
agenda.

 

As usual, and in accordance with French corporate law, the AGM comprises both
ordinary and extraordinary resolutions. All materials can be found at
www.novacyt.com/investors (http://www.novacyt.com/investors) .

 

Shareholders wishing to attend the General Meeting in person may:

 

-     For shareholders whose shares are registered with CIC: present
themselves on the day of the General Meeting, with proof of identity.

 

-    Shareholders whose shares are registered in bearer form: ask the
authorised intermediary who manages their securities account to send them a
proof of shareholding or a letter of representation, evidencing that they hold
shares of Novacyt.

 

Shareholders can also request an admission card in advance (a) from CIC
Services, by post to the following address: CIC Services Assemblées
Générales, 6 avenue de Provence 75452 Paris Cedex 09, or by email to the
following address: serviceproxy@cic.fr; or (b) on the secure VOTACCESS
platform accessible via the website
https://www.actionnaire.cic-marketsolutions.eu
(https://www.actionnaire.cic-marketsolutions.eu) .

 

Shareholders are strongly encouraged to submit their votes in advance, in
accordance with the instructions in the Notice of the AGM.

 

Shareholders can vote in advance of the AGM by:

 

·    Downloading a copy of the proxy voting form from the website
www.novacyt.com/investors (http://www.novacyt.com/investors) , completing it
and returning it together with evidence of their shareholding which must be in
the form of a share certificate (attestation) or a letter of representation
from their broker, nominee, bank or authorised intermediary, either by post to
the following address: 6 avenue de Provence 75452 Paris Cedex 09, or via email
to the following address: serviceproxy@cic.fr (mailto:serviceproxy@cic.fr) ,
or investor.relations@novacyt.com (mailto:investor.relations@novacyt.com) , no
later than 23 October 2023 inclusive.

·   Voting on-line using the Votaccess portal
http://www.actionnaire.cic-marketsolutions.eu
(http://www.actionnaire.cic-marketsolutions.eu) if securities held on Euronext
Growth are registered with any of the following banks: CIC, Natixis, Société
Générale, Caceis, Crédit Agricole, BP2S, BNP Retail, Bourse Direct, ODDO,
Rothschild Martin Maurel, Procapital, Citibank, Deutsche Bank, Bank of New
York or JP Morgan. The Votaccess portal will be open from 11 October 2023 to
25 October 2023 2pm BST/3pm CEST.

·   Voting on-line via a broker, nominee, bank or authorised intermediary.
Many intermediaries in the UK such as Hargreaves Lansdown are now using the
Broadridge ProxyVote on-line voting portal.

 

Shareholders can register to view the AGM online by visiting
https://novacytagm23.eventcaster.co.uk
(https://novacytagm23.eventcaster.co.uk) , however, they will be unable to
vote during the meeting. Registration must be accompanied by formal evidence
of shareholding.

 

Following the meeting, a recording of the AGM will be available on the
Company's website at www.novacyt.com/investors
(http://www.novacyt.com/investors) .

 

 

Contacts

 

 Novacyt SA                                                +44 (0)23 8074 8830
 James Wakefield, Non-Executive Chairman

 James McCarthy, Acting Chief Executive Officer

 SP Angel Corporate Finance LLP (Nominated Adviser and Broker)                           +44 (0)20 3470 0470

 Matthew Johnson / Charlie Bouverat (Corporate Finance)

 Vadim Alexandre / Rob Rees (Corporate Broking)

 Numis (Joint Broker)                                                                    +44 (0)20 7260 1000
 Freddie Barnfield / Duncan Monteith / Jack McLaren

 Allegra Finance (French Listing Sponsor)                                                 +33 (1) 42 22 10 10

                                                                                       r.durgetto@allegrafinance.com (mailto:r.durgetto@allegrafinance.com) /
 Rémi Durgetto / Yannick Petit                                                           y.petit@allegrafinance.com (mailto:y.petit@allegrafinance.com)

 Walbrook PR (Financial PR & IR)                           +44 (0)20 7933 8780

 Stephanie Cuthbert / Anna Dunphy / Phillip Marriage       novacyt@walbrookpr.com (mailto:novacyt@walbrookpr.com)

 

About Novacyt Group

Novacyt is an international diagnostics business delivering a broad portfolio
of in vitro and molecular diagnostic tests for a wide range of infectious
diseases, enabling faster, more accurate, accessible testing to improve
healthcare outcomes. The Company provides customers with a seamless
sample-to-result workflow using its integrated and scalable
instrumentation/solutions. The Company specialises in the design, manufacture,
and supply of real-time PCR kits, reagents and a full range of laboratory and
qPCR instrumentation for molecular biology research and clinical use. Novacyt
offers one of the world's most varied and comprehensive range of qPCR assays,
covering human, veterinary, biodefence, environmental, agriculture and food
testing.

 

The acquisition of Yourgene in September 2023 added a complementary
international genomics technology and services business, focussed on
delivering accurate molecular diagnostic and screening solutions, across
reproductive health and precision medicine. Yourgene's portfolio of in vitro
diagnostic products includes non-invasive prenatal tests (NIPT) for Down's
Syndrome and other genetic disorders, Cystic Fibrosis screening tests,
invasive rapid aneuploidy tests and DPYD genotyping assays. Yourgene also
works in partnership with global leaders in DNA technology to allow its
Ranger® Technology to deliver dynamic target enrichment.

 

Novacyt is headquartered in Vélizy in France with offices in the UK in
Stokesley, Eastleigh and Manchester. The Company also has offices in Taipei
(divestment pending), Singapore, the US and Canada and is listed on the London
Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext
Growth ("ALNOV").

 

For more information, please refer to the website: www.novacyt.com
(http://www.novacyt.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOANKKBQCBDDAKD